



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

**MINUTES OF THE MEETING HELD ON WEDNESDAY 21st FEBRUARY 2018
AT 12.30pm**

**IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL**

PRESENT:

Dr D Gavan (DG)	Consultant Radiologist ELHT (Chairperson from item 2018/36)
Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Acting chair to item 2018/35)
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Dr T McKenzie (TM)	GP, EL CCG
Dr K Burch (KB)	Consultant Microbiologist ELHT
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD

In Attendance

Ms L Prince	Medicines Management Technician EL CCG
-------------	--

2018/026: APOLOGIES:

Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Mrs L Holden (LH)	Pharmacist LCFT (representing Ms S Ramdour)

2018/027: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2018/028: MINUTES OF JANUARY MEETING:

Corrections:

2018/003 should read November (not October)

2018/014 amend spelling of Supplements

Otherwise accepted as a correct record.

2018/029: MATTERS ARISING:

Not on Action Sheet:

2018/015: ELHE: Antimicrobial Guidance for Primary Care – Nitrofurantoin preparation suitable for children for UTI needs clarifying. Check for next meeting.

2018/019: Adjuvanted Trivalent Flu Vaccine for 2018/19 Season – recommendation now updated to use for those over 65 years.

2017/162: NICE Recommendations (from Oct) – Immunosuppressive therapy for kidney transplant (TAGs 418 and 482) – Basiliximab, Tacrolimus (immediate release) and mycophenolate mofetil are Red traffic light. Rabbit anti-human thymocyte immunoglobulin, tacrolimus (prolonged release), mycophenolate sodium, sirolimus, everolimus and belatacept are not recommended and therefore Black traffic light for this indication.

From Action Sheet:

2017/137: LMMG Recommendations (from Sept) Vitamin D Position Statement - under review, draft to be shared at March meeting.

2018/013: ELHE: Prescribing Policy – Camouflage Creams & Powders – discussed links with cosmetic procedures policy, review requirements, reasonable quantities, and managing through specialist centres and/or alternative specialist arrangements. Prescribing policy agreed at last meeting still stands and products to remain red traffic light.

Deferred item

2018/012: MONITORING REQUIREMENT FOR ANTIPSYCHOTICS (SHARED CARE)

Item deferred until after meeting with LCFT to discuss monitoring requirements.

New Items

2018/030: NEW PRODUCT REQUEST – TIVOZANIB

Requested by Dr Parikh, Consultant Oncologist, for renal cell carcinoma. It appears to be more efficacious and less toxic than alternative treatments. Approved to use for suitable patients, using patient access scheme, but not for inclusion on formulary.

Resolved: Tivozanib is approved for use for renal carcinoma. Traffic light: RED

2018/031: NEW PRODUCT/ UNLICENSED REQUEST – DURVALUMAB

Requested by Dr Appel, Consultant Oncologist, for urothelial carcinoma as adjuvant following chemoradiation. Approved for use for suitable patients using patient access scheme but not for inclusion on formulary.

Resolved: Durvalumab is approved for use for urolithelial carcinoma.

Traffic light: RED

2018/032: NEW PRODUCT REQUEST – AKYNZEO®

Akynzeo® is a combination of netupitant and palonosetron as a single dose treatment lasting for 3 days, improving compliance over current 3 day regimen with aprepitant and ondansetron. It is requested by Dr Mirza, Consultant Oncologist, as second line antiemetic for use with moderately and highly emetogenic cancer chemotherapy in line with cancer network. Efficacy, safety and costs are comparable to current regimen. Approved for use to replace aprepitant regimen.

Resolved: Akynzeo® approved for formulary to replace aprepitant regimen.

Traffic light: RED

2018/033: UNLICENSED PRODUCT REQUEST – NIFEDIPINE DROPS

Requested by Dr Iqbal, Consultant Paediatrician, for Raynaud's syndrome in children. Nifedipine is standard treatment in BNFC, for Raynaud's syndrome in children. Drops required for small doses. Approved for use by paediatric consultants only.

Resolved: Nifedipine drops approved for use by paediatric consultants for Raynaud's syndrome in children.

Traffic light: RED

2018/034: NEW PRODUCT REQUEST – QV EMOLLIENT PRODUCTS

Requested by Dr Raza, GP with special interest in dermatology, as alternative cost effective emollient. As the emollient section of formulary requires review these products will be considered as part of the review.

Resolved: Request to be considered as part of review of emollient section of formulary for March/April meeting.

2018/035: LMMG CONSULTATIONS (for March LMMG)

Draft Policy for Insulin Pumps – comments sent from Dr Gardner, Consultant paediatrician.

Draft Policy for Glucose Monitoring Devices – comments sent from Dr Gardner, Consultant paediatrician.

LMWH Guidelines December 2-17 update – NOAC reference needs changing to DOAC. ELHE will continue to use local guideline.

Trelegy Recommendation – Comments received do not support use of this combination product as it doesn't currently fit with locally agreed pathway and principles around use of high potency steroids.

Resolved: Comments to be sent to LMMG

2018/036 LMMG RECOMMENDATIONS (from Jan LMMG)

Anthyperglycaemic Therapy in adults with Type 2 Diabetes

LMMG guideline accepted as written for ELHE.

Axial Spondyloarthritis Pathway

LMMG pathway accepted as written for ELHE.

Rheumatoid Arthritis High Cost Drugs Pathway

LMMG pathway accepted as written for ELHE.

NRT Position Statement – updated

ELHE will continue to use local position statement.

Specialist Infant Formula feeds Guideline - updated

LMMG updated guideline accepted as written for ELHE.

Dementia Medicines Information Sheet

LMMG information sheet accepted as written for ELHE. GP's requested clearer guidance from LCFT on when to stop treatment.

Erectile Dysfunction Guidelines – updated

LMMG updated guideline accepted as written for ELHE.

2018/037: FORMULARY UPDATES

Ciclosporin eye drops – the branded (Ikervis Unit dose®) eye drops to be changed from Red to Amber traffic light. **Traffic Light: AMBER**

Sodium phenylbutyrate 625mg/5mL, Theophylline liquid, Valproic acid liquid, Zonisamide oral suspension, Antepsin (sucralfate) 1g/5mL, Hydrocortisone oral suspension, Calamine and Coal Tar Ointment, Pyridoxine liquid, Co Careldopa Liquid – all deferred.

Resolved: Formulary to be updated as above

2018/038: DURAPHAT TOOTHPASTE IN HEAD & NECK CANCER

Letter received from Mr Moore, Consultant in Restorative Dentistry, requesting that GP's prescribe Duraphat for patients with head & neck cancer. CCG representatives raised concerns that GPs are not the appropriate professional to check dental aspects of treatments and that the dentist is the appropriate profession to provide the prescription.

Resolved: Duraphat prescribing to remain with dentists.

2018/039: NHSE: ITEMS WHICH SHOULD NOT ROUTINELY BE PRESCRIBED IN PRIMARY CARE: GUIDANCE FOR CCGs

NHSE document for information of advice provided to CCGs. The local CCGs have incorporated this into their workplans for implementation 2018-19. Document to be sent out within the trust to increase awareness.

Resolved: For information.

2018/040: HOMELY REMEDIES POLICY

The policy guides use of homely remedies in care homes. ELMMB was not supportive of the recommendations 'to contact the GP' as a first port of call and suggested local commissioning arrangements should be considered. For example a number of areas provide support to care homes through Telemedicine nurses and care home nurse practitioners who would be a more suitable contact. Policy to be reviewed and brought back to ELMMB in March/April.

Resolved: Policy for homely remedies to be reviewed.

2018/041: ELCCG: DVT PRIMARY CARE PATHWAY

This latest version of the pathway is now finalised. Accepted for use.

Resolved: DVT Primary Care Pathway accepted for use.

2018/042: NICE RECOMMENDATIONS (from Jan)

Golimumab for treating non-radiographic axial spondyloarthritis [TAG 497] is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned: Blueteq form required

Traffic Light: RED

Lenvatinib with everolimus for previously treated advanced renal cell carcinoma [TAG 498] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Glecaprevir–pibrentasvir for treating chronic hepatitis C (TAG 499) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Ceritinib for untreated ALK-positive non-small-cell lung cancer [TAG 500] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TAG 501) is not recommended as an option by NICE. (Non-drug)

Traffic Light: BLACK

Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TAG 502) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TAG 503) is not recommended as an option by NICE.

Traffic Light: BLACK

STANDING ITEMS

2018/043: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – Jan 2018

Minutes acknowledged

2018/044: FOR ACTION/INFORMATION: LANCASHIRE CARE FT D & T MINUTES – Dec 2017

Minutes acknowledged

2018/045: FOR ACTION/INFORMATION: LANCASHIRE CARE FT D & T MINUTES – Jan 2018

Minutes acknowledged

DATE OF NEXT MEETING – Wednesday 21st March 2018 12.30pm, Pharmacy Seminar Room, Pharmacy Department, RBH.

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 21ST FEBRUARY 2018

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2017/137	LMMG Recommendations (from Sept) Vitamin D Position Statement – to be considered together with ELHE guidelines & products used	JV	Feb 18
2018/015	ELHE: Antimicrobial Guidance for Primary Care – Nitrofurantoin preparation for children	CD/ CW	Mar 18
2018/040	Homely Remedies Policy – review	LR	Mar / Apr 18